Browsing "Comunicações em Eventos - LIM/24" by Title

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 367 to 386 of 577 < previous   next >
Issue DateTitleAuthor(s)
2016p16 expression and its prognostic impact in HNSCC pts in Bel'm-Brazil.GOMES, Amanda Raquel da Silva; BARRA, Williams Fernandes; BECHARA, Millene A.; COSTA, Juliana P. N. da; CARVALHO, Maria Fernanda V. L. de; SILVA, Carlos Augusto; MAGALHAES, Jose L. L.; NASCIMENTO, Eliude R.; PACHECO, Fernando Chalu; CASTRO, Gilberto
2022PALBOCICLIB PLUS LETROZOLE COMBINATION AFTER PROGRESSION ON SECOND-LINE CHEMOTHERAPY FOR WOMEN WITH ER/PR-POSITIVE HIGH-GRADE SEROUS OR ENDOMETRIOID OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER (LACOG 1018)DAMIAN, Fernanda; MOLIN, Graziela Zibetti Dal; RODRIGUES, Angelica; CALABRICH, Aknar De Carvalho; WERUTSKY, Gustavo; FILHO, Elias Abdo; JIMENEZ, Mirela Foresti; REBELATTO, Taiane; JESUS, Rafaela De; MELO, Andreia Cristina De
2018Palliative chemotherapy for patient with advanced tumor and poor performance status: Are oncologists' hopes of benefit justified?VASCONCELLOS, V. F.; BONADIO, R. R. C. C.; AVANCO, G.; NEGRAO, M. V.; RIECHELMANN, R.
2013Palliative chemotherapy in patients with malignant bowel obstructionMUNIZ, D. Q.; MAK, M. P.; BITTON, R. C.; TAKAHASHI, T. K.; SARAGIOTTO, D. F.; ABDO, E.; SABBAGA, J.; HOFF, P. M.
2021Pancreatoduodenectomy With and Without Venous Resection for Pancreatic Cancer: A Systematic Review and Meta-analysisLEMOS FILHO, P. Joao Emilio; CABRAL, Fernanda C.; TUSTUMI, Francisco; DIAS, Andre R.; HENRIQUES, Alexandre C.; FUHRO, Felipe E.; WAISBERG, Jaques; JUNIOR, Sergio S.
2019PARA AORTIC LYMPH NODES INVOLVEMENT IN CERVICAL CANCER PATIENTS: RECURRENCE, SURVIVAL, TREATMENT AND ADVERSE EVENTSDIZ, M. Del Pilar Estevez; MIRANDA, V. C.; CAVALHEIRO, V. J.; GABRIELLI, F.; MAIA, K. F. S. D. O.
2016Pathogenic Copy Number Variants are Frequently Identified in Children with Short Stature of Unknown EtiologyCANTON, Ana; HOMMA, Thais; FURUYA, Tatiane; ROELA, Rosimeire; ARNHOLD, Ivo; JORGE, Alexander
2017Patterns of post-operative radiotherapy in breast cancer patients after neoadjuvant chemotherapyLOPES, K. M.; FREITAS, T. B. De; CARVALHO, H. A.; PEREIRA, A. A.; SILVA, S. B.; STUART, S. R.; MANO, M. S.; FILASSI, J. R.; MARTA, G. N.
2021PD-L1 Expression in Gastric Cancer: Correlation Between the Primary Site and Metastatic Lymph NodeCOIMBRA, Brendha C.; PEREIRA, Marina A.; CARDILI, Leonardo; RAMOS, Marcus Fernando Kodama P.
2015PDIA1 overexpression activates acutely Nox1 NADPH oxidase in VSMCGONCALVES, Renata; ZANATA, Daniela; STRAUSS, Bryan; LAURINDO, Francisco Rafael; FERNANDES, Denise de Castro
2020Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.RISCHIN, Danny; HARRINGTON, Kevin Joseph; GREIL, Richard; SOULIERES, Denis; TAHARA, Makoto; CASTRO, Gilberto; PSYRRI, Amanda; BASTE, Neus; NEUPANE, Prakash C.; BRATLAND, Ase, et al
2022Pembrolizumab (pembro) plus carboplatin (carbo) plus paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 studyDZIENIS, M. R.; CUNDOM, J. E.; FUENTES, C. S.; HANSEN, A. R.; NORDLINGER, M. J.; PASTOR, A. V.; OPPELT, P.; NEKI, A.; GREGG, R. W.; LIMA, I. P. F., et al
2018Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3 KEYNOTE-042 study.LOPES, Gilberto; WU, Yi-Long; KUDABA, Iveta; KOWALSKI, Dariusz; CHO, Byoung Chul; CASTRO, Gilberto; SRIMUNINNIMIT, Vichien; BONDARENKO, Igor; KUBOTA, Kaoru; LUBINIECKI, Gregory M., et al
2016Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1-expressing NSCLC: Updated outcomes of KEYNOTE-010HERBST, R. S.; BAAS, P.; KIM, D-W.; FELIP, E.; PEREZ-GRACIA, J. L.; HAN, J-Y.; MOLINA, J.; KIM, J-H.; ARVIS, C. Dubos; AHN, M-J. A., et al
2016Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%; Results from KEYNOTE-010.GARON, Edward B.; HERBST, Roy S.; KIM, Dong-Wan; FELIP, Enriqueta; PEREZ-GRACIA, Jose Luis; HAN, Ji-Youn; KIM, Joo-Hang; ARVIS, Catherine Dubos; AHN, Myung-Ju; MAJEM, Margarita, et al
2016Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 AssessmentHERBST, Roy S.; BAAS, Paul; PEREZ-GRACIA, Jose L.; FELIP, Enriqueta; KIM, Dong-Wan; HAN, Ji-Youn; MOLINA, Julian; KIM, Joo-Hang; ARVIS, Catherine Dubos; AHN, Myung-Ju, et al
2016Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 AssessmentHERBST, Roy S.; BAAS, Paul; PEREZ-GRACIA, Jose L.; FELIP, Enriqueta; KIM, Dong-Wan; HAN, Ji-Youn; MOLINA, Julian; KIM, Joo-Hang; ARVIS, Catherine Dubos; AHN, Myung-Ju, et al
2022Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048TAHARA, M.; GREIL, R.; RISCHIN, D.; HARRINGTON, K. J.; BURTNESS, B.; CASTRO JR., G. De; PSYRRI, A.; BRANA, I.; NEUPANE, P.; BRATLAND, A., et al
2022Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trialWAINBERG, Zev A.; SHITARA, Kohei; CUTSEM, Eric Van; WYRWICZ, Lucjan; LEE, Keun Wook; KUDABA, Iveta; GARRIDO, Marcelo; CHUNG, Hyun Cheol Cheol; LEE, Jeeyun; CASTRO-SALGUERO, Hugo Raul, et al
2012Percutaneous transhepatic biliary drainage (PTBD) in patients (pts) with advanced solid malignancies: Clinical outcomes and prognostic factorsCROSARA, Marcela Alves Teixeira; MAK, Milena P.; MARQUES, Daniel Fernandes; CAPARELI-AZEVEDO, Fernanda C.; HOFF, Paulo Marcelo
Showing results 367 to 386 of 577 < previous   next >